Overview
Sulfhemoglobinemia is a rare condition characterized by the presence of sulfhemoglobin, a sulfur-containing derivative of hemoglobin, leading to persistent cyanosis without significant hypoxia 1.Diagnosis
Elevated levels of sulfhemoglobin in blood (typically > 1%) confirmed by specialized spectrophotometric methods 1.
Clinical presentation includes persistent cyanosis unresponsive to oxygen therapy.
Exclusion of other causes of cyanosis through comprehensive evaluation including arterial blood gases and imaging 1.Management
First-line: Identify and discontinue exposure to sulfur-containing compounds (e.g., certain medications, industrial chemicals).
Adjunctive: Supportive care including oxygen therapy to manage symptoms, though it does not affect sulfhemoglobin levels 1.
Monitoring: Regular follow-up to monitor sulfhemoglobin levels as spontaneous resolution can occur over weeks to months 1.Special Populations
Pregnancy: Limited data; management focuses on identifying and removing exposure risks 1.
Pediatrics: Similar principles apply; careful monitoring for developmental impacts due to prolonged cyanosis 1.
Elderly: Increased vigilance for underlying comorbidities that may complicate diagnosis and management 1.
Comorbidities: Focus on managing underlying conditions while addressing sulfhemoglobinemia 1.Key Recommendations
Identify and eliminate exposure to sulfur-containing substances as the primary intervention (Evidence: Expert opinion 1).
Monitor sulfhemoglobin levels regularly to assess resolution without specific pharmacological treatment (Evidence: Expert opinion 1).
Provide supportive care including oxygen therapy to manage symptoms, acknowledging its limited impact on sulfhemoglobin levels (Evidence: Expert opinion 1).References
1 Wallace JL, Vaughan D, Dicay M, MacNaughton WK, de Nucci G. Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. Antioxidants & redox signaling 2018. link
2 Wu D, Hu Q, Xiong Y, Zhu D, Mao Y, Zhu YZ. Novel H. Redox biology 2018. link